

Intermountain Precision Genomics
600 S. Medical Drive, Suite 101 • St. George, Utah 84790
Phone: 435.251.5780
Laboratory Director: Jeremy Wallentine
CLIA ID Number: 46D2094383
Intermountain.com/RxMatch





This report combines (i) an analysis of the patient's DNA by Intermountain Precision Genomics, identifying relevant genetic variants that are informative for medication efficacy, safety, and dosing, with (ii) an interpretation of the identified DNA variants by Coriell Life Sciences to bring you immediately actionable clinical guidance regarding safer, more effective medications and dosages for the patient. The Medication Report section lists the type of PGx guidance present on FDA-approved drug labels. Medications with no established FDA PGx guidance are provided solely for educational purposes.

Patient: XYTEST, Name
Date of Birth: Jan 01, 1940
Gender: Unknown

Physician: Dr. Example
Practice: Example Health Associates

Sample ID: RS-21-0000052A





Medication Summary





Therapeutic Class	 Standard Precautions	  Caution / Info	 Change recommended
Alpha-1 Blockers	Tamsulosin		
Anti-ADHD Agents	Atomoxetine Clonidine Guanfacine Methylphenidate (ADRA2A)	Amphetamine Dexmethylphenidate Dextroamphetamine Lisdexamfetamine Methylphenidate (COMT)	
Antiarrhythmics	Flecainide Propafenone		
Anticholinergic Agents	Fesoterodine Tolterodine		
Anticoagulants		Warfarin	
Anticonvulsants	Phenytoin	Brivaracetam Clobazam	
Antidementia Agents	Donepezil		
Antidepressants	Amoxapine		Amitriptyline (CYP2C19,





RS-21-0000052A - XYTEST, Name - Reported Aug 17, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history and current treatment regimen. Portions © 2014-2021 Coriell Life Sciences, Inc.






Powered by:
CORIELL
LIFE SCIENCES

Therapeutic Class	 Standard Precautions	  Caution / Info	 Change recommended
	Desipramine Duloxetine Mirtazapine Nortriptyline Protriptyline Trazodone Venlafaxine Vortioxetine		CYP2D6) Clomipramine (CYP2C19, CYP2D6) Doxepin (CYP2C19, CYP2D6) Imipramine (CYP2C19, CYP2D6) Trimipramine (CYP2C19, CYP2D6)
Antidiabetics	Glimepiride Glyburide Saxagliptin Tolbutamide		
Antiemetics	Ondansetron		
Antifungals	Ketoconazole		Voriconazole
Antineoplastic Agents			Methotrexate
Antiplatelet Agents	Prasugrel Ticagrelor		Clopidogrel
Antipsychotics	Aripiprazole Brexpiprazole Clozapine Haloperidol Iloperidone Olanzapine Perphenazine Pimozide Quetiapine Risperidone Thioridazine		
Anxiolytics	Alprazolam Buspirone Clonazepam	Diazepam	
Beta-3 Adrenergic Agonists	Mirabegron		
Beta Blockers	Carvedilol		

Therapeutic Class	 Standard Precautions	  Caution / Info	 Change recommended
	Metoprolol Nebivolol Propranolol Timolol		
Central Monoamine-Depleting Agents	Tetrabenazine		
Central Nervous System Agents	Dextromethorphan-Quinidine		
Cholinergic Agonists	Cevimeline		
Cholinesterase Inhibitors	Galantamine		
Contraceptives	Estrogen-containing oral contraceptives		
EGFR Inhibitors	Gefitinib		
Endocrine-Metabolic Agents	Eliglustat		
Estrogen Agonists/Antagonists	Tamoxifen		
Hypnotics	Eszopiclone		
Immunosuppressants	Azathioprine Cyclosporine Mercaptopurine Sirolimus Thioguanine	Tacrolimus	
Muscle Relaxants		Carisoprodol	
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	Celecoxib Diclofenac Flurbiprofen Ibuprofen Meloxicam		

Therapeutic Class	 Standard Precautions	  Caution / Info	 Change recommended
	Piroxicam		
Opioids	Alfentanil Buprenorphine Codeine Fentanyl Fentanyl (OPRM1) Hydrocodone Hydromorphone Morphine Oxycodone Oxycodone (CYP3A4) Sufentanil Tramadol	Oxycodone (CYP3A5)	
Prokinetic agents	Metoclopramide		
Proton Pump Inhibitors (PPIs)		Dexlansoprazole Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole	
Selective Serotonin Reuptake Inhibitors (SSRIs)	Fluoxetine Fluvoxamine Paroxetine	Citalopram Escitalopram Sertraline	
Statins	Atorvastatin Simvastatin		
Vesicular monoamine transporter 2 inhibitor	Deutetrabenazine Valbenazine		
Xanthine Oxidase Inhibitor	Allopurinol		



Legend






-  Typical response is expected
-  Caution - review recommendation
-  Change recommended
-  Additional information available
-  Response is uncertain

Clinical Evidence Level

-  Strong
-  Moderate
-  Emerging













Medication Report Details (by therapeutic class)











Drug	Finding	Recommendation	Concern	Evidence
Alpha-1 Blockers				
Tamsulosin (Flomax) <i>FDA drug label:</i> <i>Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		













Drug	Finding	Recommendation	Concern	Evidence
Anti-ADHD Agents				
Amphetamine (Adzenys, Evekeo) <i>FDA drug label: Not established for PGx</i>	 COMT(Val158Met): Decreased function. One normal function allele and one decreased function allele.	Individuals with decreased function of this gene may present with increased risk of pharmacotherapy failure. Be alert to lack of efficacy.	Efficacy	
Atomoxetine (Strattera) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Clonidine (Clonidine, Kapvay) <i>FDA drug label: Not established for PGx</i>	 ADRA2A(C-1291G): Two wild-type alleles.	Typical response is expected; no additional therapeutic recommendations.		
Dexmethylphenidate (Focalin) <i>FDA drug label: Not established for PGx</i>	 COMT(Val158Met): Decreased function. One normal function allele and one decreased function allele.	Individuals with decreased function of this gene may present with increased risk of pharmacotherapy failure. Be alert to lack of efficacy.	Efficacy	
Dextroamphetamine (Zenzedi, Dexedrine) <i>FDA drug label: Not established for PGx</i>	 COMT(Val158Met): Decreased function. One normal function allele and one decreased function allele.	Individuals with decreased function of this gene may present with increased risk of pharmacotherapy failure. Be alert to lack of efficacy.	Efficacy	
Guanfacine (Tenex, Intuniv) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Lisdexamfetamine (Vyvanse) <i>FDA drug label: Not established for PGx</i>	 COMT(Val158Met): Decreased function. One normal function allele and one decreased function allele.	Individuals with decreased function of this gene may present with increased risk of pharmacotherapy failure. Be alert to lack of efficacy.	Efficacy	

RS-21-0000052A - XYTEST, Name - Reported Aug 17, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history and current treatment regimen. Portions © 2014-2021 Coriell Life Sciences, Inc.














Drug	Finding	Recommendation	Concern	Evidence
Methylphenidate (ADRA2A) (Concerta, Metadate, Ritalin, Ritalin LA, Quillivant, Daytrana, Methylin) <i>FDA drug label: Not established for PGx</i>	 ADRA2A(C-1291G): Two wild-type alleles.	Typical response is expected; no additional therapeutic recommendations.		
Methylphenidate (COMT) (Concerta, Metadate, Ritalin, Ritalin LA, Quillivant, Daytrana, Methylin) <i>FDA drug label: Not established for PGx</i>	 COMT(Val158Met): Decreased function. One normal function allele and one decreased function allele.	Individuals with decreased function of this gene may present with increased risk of pharmacotherapy failure. Be alert to lack of efficacy.	Efficacy	
Antiarrhythmics				
Flecainide (Tambocor) <i>FDA drug label: Not established for PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Propafenone (Rythmol) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Anticholinergic Agents				
Fesoterodine (Toviaz) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Tolterodine (Detrol) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		












Drug	Finding	Recommendation	Concern	Evidence
Anticoagulants				
Warfarin (Coumadin) <i>FDA drug label:</i> Actionable PGx	 Multigenic: VKORC1, CYP2C9: Normal metabolizer. Two normal function alleles.	Individuals with this combination of alleles may benefit from an increased dose of Warfarin. The FDA table recommends a therapeutic dose of 5-7 mg/day.		
Anticonvulsants				
Brivaracetam <i>FDA drug label:</i> Actionable PGx	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication may present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose.	ADR	
Clobazam (Onfi) <i>FDA drug label:</i> Actionable PGx	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication may present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose; monitor the patient's response to guide dosing.	ADR	
Phenytoin (Dilantin) <i>FDA drug label:</i> Actionable PGx	 CYP2C9: Normal metabolizer. Two alleles showing normal activity.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Antidementia Agents				
Donepezil (Aricept) <i>FDA drug label:</i> Actionable PGx	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		








Drug	Finding	Recommendation	Concern	Evidence
Antidepressants				
Amitriptyline (CYP2C19, CYP2D6) (Elavil) <i>FDA drug label: Not established for PGx</i>	 Multigenic: CYP2D6, CYP2C19: Normal metabolizer. Two alleles showing normal function.; Poor metabolizer. Two little or no function alleles.	Individuals with this combination of alleles frequently present with significantly increased risk of side effects. This medication should be avoided.	ADR	
Amoxapine (Asendin) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Clomipramine (CYP2C19, CYP2D6) (Anafranil, Clomicalm) <i>FDA drug label: Not established for PGx</i>	 Multigenic: CYP2D6, CYP2C19: Normal metabolizer. Two alleles showing normal function.; Poor metabolizer. Two little or no function alleles.	Individuals with this combination of alleles frequently present with significantly increased risk of side effects. This medication should be avoided.	ADR	
Desipramine (Norpramin) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Doxepin (CYP2C19, CYP2D6) (Quitaxon, Aponal, Sinequan) <i>FDA drug label: Actionable PGx</i>	 Multigenic: CYP2D6, CYP2C19: Normal metabolizer. Two alleles showing normal function.; Poor metabolizer. Two little or no function alleles.	Individuals with this combination of alleles frequently present with significantly increased risk of side effects. This medication should be avoided.	ADR	
Duloxetine (Cymbalta) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		







RS-21-0000052A - XYTEST, Name - Reported Aug 17, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history and current treatment regimen. Portions © 2014-2021 Coriell Life Sciences, Inc.















Drug	Finding	Recommendation	Concern	Evidence
Imipramine (CYP2C19, CYP2D6) (Tofranil-PM, Tofranil) <i>FDA drug label: Actionable PGx</i>	 Multigenic: CYP2D6, CYP2C19: Normal metabolizer. Two alleles showing normal function.; Poor metabolizer. Two little or no function alleles.	Individuals with this combination of alleles frequently present with significantly increased risk of side effects. This medication should be avoided.	ADR	
Mirtazapine <i>FDA drug label: Not established for PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Typical response expected. No additional therapeutic recommendations.		
Nortriptyline (Pamelor) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Protriptyline (Vivactil) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Trazodone (Oleptro, Desyrel) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Trimipramine (CYP2C19, CYP2D6) (Surmontil) <i>FDA drug label: Not established for PGx</i>	 Multigenic: CYP2D6, CYP2C19: Normal metabolizer. Two alleles showing normal function.; Poor metabolizer. Two little or no function alleles.	Individuals with this combination of alleles frequently present with significantly increased risk of side effects. This medication should be avoided.	ADR	
Venlafaxine (Effexor) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		















Drug	Finding	Recommendation	Concern	Evidence
Vortioxetine (Brintellix) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Antidiabetics				
Glimepiride <i>FDA drug label: Not established for PGx</i>	 CYP2C9: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Glyburide (Glibenclamide) <i>FDA drug label: Not established for PGx</i>	 CYP2C9: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Saxagliptin (Onglyza) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Tolbutamide (Orinase) <i>FDA drug label: Not established for PGx</i>	 CYP2C9: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Antiemetics				
Ondansetron (Zofran) <i>FDA drug label: Informative PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		













Drug	Finding	Recommendation	Concern	Evidence
Antifungals				
Ketoconazole (Nizoral) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Voriconazole (Vfend) <i>FDA drug label: Actionable PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication frequently present with notably higher plasma concentrations of the active medication, thus a significantly increased risk of side effects. This medication should be avoided.	ADR	
Antineoplastic				
Cisplatin (Platinol) <i>FDA drug label: Not established for PGx</i>	 TPMT: *1 *1	No recommendation for Cisplatin is available for this combination of variants/alleles.		
Antineoplastic Agents				
Methotrexate (Rheumatrex, Trexall) <i>FDA drug label: Not established for PGx</i>	 MTHFR: Decreased function. One normal function allele and one decreased function allele.	Individuals with decreased function of this gene frequently present with significantly increased risk of side effects. This medication should be avoided.	ADR	





Drug	Finding	Recommendation	Concern	Evidence
Antiplatelet Agents				
Clopidogrel <i>FDA drug label: Actionable PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication frequently present with notably lower plasma concentrations of the active medication, thus a significantly increased risk of pharmacotherapy failure. This medication should be avoided.	Efficacy	
Prasugrel <i>FDA drug label: Informative PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Typical response expected. No additional therapeutic recommendations.		
Ticagrelor (Brilinta) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		








Drug	Finding	Recommendation	Concern	Evidence
Antipsychotics				
Aripiprazole (Abilify) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Brexipiprazole (Rexulti) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Clozapine <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Haloperidol (Haldol) <i>FDA drug label: Not established for PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Iloperidone <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Olanzapine (Zalasta, Zyprexa) <i>FDA drug label: Not established for PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Typical response expected. No additional therapeutic recommendations.		
Perphenazine (Trilafon) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Pimozide (Orap) <i>FDA drug label: Testing required</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		



Drug	Finding	Recommendation	Concern	Evidence
Quetiapine (Seroquel) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Risperidone (Risperdal) <i>FDA drug label: Informative PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Thioridazine <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Anxiolytics				
Alprazolam (Xanax, Niravam) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Buspirone (Buspar) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Clonazepam (Klonopin) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Diazepam <i>FDA drug label: Actionable PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication may present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Be alert to adverse reactions; monitor the patient's response to guide dosing.	ADR	

Drug	Finding	Recommendation	Concern	Evidence
Beta-3 Adrenergic Agonists				
Mirabegron (Myrbetriq) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Beta Blockers				
Carvedilol (Coreg) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Metoprolol (Lopressor) <i>FDA drug label: Informative PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Nebivolol (Bystolic) <i>FDA drug label: Informative PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Typical response expected. No additional therapeutic recommendations.		
Propranolol (Inderal) <i>FDA drug label: Informative PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Typical response expected. No additional therapeutic recommendations.		
Timolol (Blocadren) <i>FDA drug label: Not established for PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Central Monoamine-Depleting Agents				
Tetrabenazine (Xenazine) <i>FDA drug label: Testing required</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		














Drug	Finding	Recommendation	Concern	Evidence
Central Nervous System Agents				
Dextromethorphan-Quinidine (Nuedexta) <i>FDA drug label: Testing recommended</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Cholinergic Agonists				
Cevimeline (Evoxac) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Cholinesterase Inhibitors				
Galantamine (Razadyne, Razadyne ER, Nivalin, Lycopremine, Reminyl) <i>FDA drug label: Informative PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Contraceptives				
Estrogen-containing oral contraceptives <i>FDA drug label: Not established for PGx</i>	 F5: Two wild-type alleles.	Individuals with wild type alleles are expected to show typical response. No additional therapeutic recommendations.		
EGFR Inhibitors				
Gefitinib (Iressa) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Endocrine-Metabolic Agents				
Eliglustat <i>FDA drug label: Testing required</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		










Drug	Finding	Recommendation	Concern	Evidence
Estrogen Agonists/Antagonists				
Tamoxifen (Soltamox, Nolvadex) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Hypnotics				
Eszopiclone (Lunesta) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		















Drug	Finding	Recommendation	Concern	Evidence
Immunosuppressants				
Azathioprine (Imuran) <i>FDA drug label: Testing recommended</i>	 TPMT: Normal metabolizer. Two alleles showing normal activity.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Cyclosporine (Gengraf, Neoral) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Mercaptopurine (Purinethol) <i>FDA drug label: Testing recommended</i>	 TPMT: Normal metabolizer. Two alleles showing normal activity.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Sirolimus (Rapamune) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Tacrolimus (Prograf, Hecoria) <i>FDA drug label: Not established for PGx</i>	 CYP3A5: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication frequently present with higher plasma concentrations of the active medication, frequently present with increased medication efficacy. No additional therapeutic recommendations.	Efficacy	
Thioguanine (6-TG, Tabloid, Lanvis) <i>FDA drug label: Testing recommended</i>	 TPMT: Normal metabolizer. Two alleles showing normal activity.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		









Drug	Finding	Recommendation	Concern	Evidence
Muscle Relaxants				
<p>Carisoprodol (Soma)</p> <p><i>FDA drug label:</i> <i>Actionable PGx</i></p>	<p> CYP2C19: Poor metabolizer. Two little or no function alleles.</p>	<p>Poor metabolizers of this medication may present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Be alert to adverse reactions, or consider alternative medication.</p>	<p>ADR</p>	<p></p>





Drug	Finding	Recommendation	Concern	Evidence
Non-drug				
ABCG2	 ABCG2: Normal function. Two normal function alleles.	Typical response is expected; no additional therapeutic recommendations.		
ADRA2A(C-1291G)	 ADRA2A(C-1291G): Two wild-type alleles.	Typical response is expected; no additional therapeutic recommendations.		
COMT(Val158Met)	 COMT(Val158Met): Decreased function. One normal function allele and one decreased function allele.	No additional therapeutic recommendations.		
CYP1A2	 CYP1A2: *1A *1L	No additional therapeutic recommendations.		
DPYD	 DPYD: Normal metabolizer. Two alleles showing normal activity.	Typical response is expected; no additional therapeutic recommendations.		
G6PD	 G6PD: Normal function. Two alleles of Class IV variants which are normal (60-150% function).	Typical response is expected; no additional therapeutic recommendations.		
GRIK4	 GRIK4: Indeterminate function. One normal function allele and one altered function allele.	Uncertain function. One allele with normal activity and one with altered activity.		
HTR2A	 HTR2A: Indeterminate function. One normal function allele and one altered function allele.	Uncertain function. One allele with normal activity and one with altered activity.		













Drug	Finding	Recommendation	Concern	Evidence
OPRM1(A118G)	 OPRM1(A118G): Normal function. Two alleles with normal activity.	Normal function. Two alleles with normal activity.		
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)				
Celecoxib (Celebrex) <i>FDA drug label: Actionable PGx</i>	 CYP2C9: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Diclofenac (Cataflam) <i>FDA drug label: Not established for PGx</i>	 CYP2C9: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Flurbiprofen (Ocufer) <i>FDA drug label: Actionable PGx</i>	 CYP2C9: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Ibuprofen (Motrin, Advil) <i>FDA drug label: Not established for PGx</i>	 CYP2C9: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Meloxicam (Mobic) <i>FDA drug label: Actionable PGx</i>	 CYP2C9: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Piroxicam (Feldene) <i>FDA drug label: Actionable PGx</i>	 CYP2C9: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		











Drug	Finding	Recommendation	Concern	Evidence
Opioids				
Alfentanil (Rapifen, Alfenta) <i>FDA drug label: Not established for PGx</i>	 OPRM1(A118G): Normal function. Two alleles with normal activity.	Individuals with normal function of this gene are expected to show typical response. No additional therapeutic recommendations.		
Buprenorphine (Butrans, Buprenex) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Codeine <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Fentanyl (Duragesic, Sublimaze) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Fentanyl (OPRM1) (Duragesic, Sublimaze) <i>FDA drug label: Not established for PGx</i>	 OPRM1(A118G): Normal function. Two alleles with normal activity.	Individuals with normal function of this gene are expected to show typical response. No additional therapeutic recommendations.		
Hydrocodone <i>FDA drug label: Not established for PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Hydromorphone (Dilaudid) <i>FDA drug label: Not established for PGx</i>	 OPRM1(A118G): Normal function. Two alleles with normal activity.	Individuals with normal function of this gene are expected to show typical response. No additional therapeutic recommendations.		

Drug	Finding	Recommendation	Concern	Evidence
Morphine (MS-IR) <i>FDA drug label: Not established for PGx</i>	 OPRM1(A118G): Normal function. Two alleles with normal activity.	Individuals with normal function of this gene are expected to show typical response. No additional therapeutic recommendations.		
Oxycodone (Oxycontin) <i>FDA drug label: Not established for PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Typical response expected. No additional therapeutic recommendations.		
Oxycodone (CYP3A4) (Oxycontin) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Normal metabolizer. Two normal function alleles.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Oxycodone (CYP3A5) (Oxycontin) <i>FDA drug label: Not established for PGx</i>	 CYP3A5: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication may present with notably lower plasma concentrations of the active medication, thus an increased risk of pharmacotherapy failure. Be alert to lack of efficacy; monitor the patient's response to guide dosing.	Efficacy	
Sufentanil (Sufenta) <i>FDA drug label: Not established for PGx</i>	 OPRM1(A118G): Normal function. Two alleles with normal activity.	Individuals with normal function of this gene are expected to show typical response. No additional therapeutic recommendations.		
Tramadol (Ultracet, Ultram) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Prokinetic agents				
Metoclopramide (Primperan, Reglan) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		

Drug	Finding	Recommendation	Concern	Evidence
Proton Pump Inhibitors (PPIs)				
Dexlansoprazole (Dexilant, Kapidex) <i>FDA drug label: Actionable PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication frequently present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose; monitor the patient's response to guide dosing.	ADR	
Esomeprazole (Nexium) <i>FDA drug label: Actionable PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication may present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose; monitor the patient's response to guide dosing.	ADR	
Lansoprazole (Prevacid) <i>FDA drug label: Informative PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication frequently present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose; monitor the patient's response to guide dosing.	ADR	
Omeprazole (Prilosec, Zegerid) <i>FDA drug label: Actionable PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication frequently present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose; monitor the patient's response to guide dosing.	ADR	

Drug	Finding	Recommendation	Concern	Evidence
<p>Pantoprazole (Protonix) <i>FDA drug label: Actionable PGx</i></p>	<p> CYP2C19: Poor metabolizer. Two little or no function alleles.</p>	<p>Poor metabolizers of this medication frequently present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose; monitor the patient's response to guide dosing.</p>	<p>ADR</p>	<p></p>
<p>Rabeprazole (Aciphex) <i>FDA drug label: Actionable PGx</i></p>	<p> CYP2C19: Poor metabolizer. Two little or no function alleles.</p>	<p>Poor metabolizers of this medication may present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose; monitor the patient's response to guide dosing.</p>	<p>ADR</p>	<p></p>

Drug	Finding	Recommendation	Concern	Evidence
Selective Serotonin Reuptake Inhibitors (SSRIs)				
Citalopram (Celexa) <i>FDA drug label: Actionable PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication may present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose, or using an alternative medication.	ADR	
Escitalopram (Lexapro) <i>FDA drug label: Actionable PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication may present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose, or using an alternative medication.	ADR	
Fluoxetine (Prozac) <i>FDA drug label: Informative PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Typical response expected. No additional therapeutic recommendations.		
Fluvoxamine (Luvox) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Paroxetine (Paxil) <i>FDA drug label: Informative PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Sertraline (Zoloft) <i>FDA drug label: Not established for PGx</i>	 CYP2C19: Poor metabolizer. Two little or no function alleles.	Poor metabolizers of this medication frequently present with notably higher plasma concentrations of the active medication, thus an increased risk of side effects. Consider reducing the dose, or using an alternative medication.	ADR	

Drug	Finding	Recommendation	Concern	Evidence
Statins				
Atorvastatin (Lipitor, Caduet) <i>FDA drug label: Not established for PGx</i>	 CYP3A4: Extensive metabolizer. Two alleles showing normal activity.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Simvastatin (Zocor) <i>FDA drug label: Informative PGx</i>	 SLC01B1: Normal liver uptake activity.	Individuals with normal SLC01B1 liver uptake activity are expected to have a typical response to a standard dose of simvastatin.		
Vesicular monoamine transporter 2 inhibitor				
Deutetrabenazine (Austedo) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Valbenazine (Ingrezza) <i>FDA drug label: Actionable PGx</i>	 CYP2D6: Normal metabolizer. Two alleles showing normal function.	Normal metabolizers of this medication are expected to show typical response. No additional therapeutic recommendations.		
Xanthine Oxidase Inhibitor				
Allopurinol (Zyloprim) <i>FDA drug label: Not established for PGx</i>	 ABCG2: Normal function. Two normal function alleles.	Individuals with normal function of this gene are expected to show typical response. No additional therapeutic recommendations.		

Thrombosis Profile

Tested Gene (Allele)	Genotype	Predicted Phenotype	Clinical Guidance
Prothrombin (F2)	Normal	Normal risk expected based on the patient's genotype.	The absence of these variant alleles of Prothrombin (Factor II) and Factor V Leiden suggests that the patient does not have the elevated risk of thrombosis associated with these genetic markers.
Factor V Leiden	Normal		
MTHFR (A1298C)	Homozygous variant		
MTHFR (C677T)	Normal		

General Description

Genetic analyses of three genes (four alleles) considered to increase the risk for venous thromboembolism were performed using molecular genetic techniques. The presence of the Prothrombin (Factor 2) gene allele c.*97G>A (previously designated as 20210G>A) and Factor V Leiden allele c.1601G>A (previously designated as 1691G>A) are risk factors for venous thromboembolism. This risk may be further increased by the use of estrogen therapy, oral contraceptives, pregnancy, and surgery.

Patients who are homozygous for MTHFR C677T or MTHFR A1298C may have a further increased risk for venous thromboembolism if they also possess the Factor V Leiden c.1601G>A allele. However, the MTHFR alleles alone do not predict a significant risk for venous thromboembolism.

References

- Zhang S, et al.; ACMG Laboratory Quality Assurance Committee. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2018 Dec;20(12):1489-1498. doi: 10.1038/s41436-018-0322-z. Epub 2018 Oct 5. PMID: 30297698.
- Bhatt S, et al.; ACMG Professional Practice and Guidelines Committee. Addendum: American College of Medical Genetics consensus statement on factor V Leiden mutation testing. *Genet Med.* 2021 Mar 5. doi: 10.1038/s41436-021-01108-x. Epub ahead of print. PMID: 33674767.
- Lim MY, et al.; Thrombophilic risk of individuals with rare compound factor V Leiden and prothrombin G20210A polymorphisms: an international case series of 100 individuals. *Eur J Haematol.* 2016 Oct;97(4):353-60. doi: 10.1111/ejh.12738. Epub 2016 Feb 18. PMID: 26773706.
- Saemundsson Y, et al.; Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation. *J Thromb Thrombolysis.* 2013 Oct;36(3):324-31. doi: 10.1007/s11239-012-0824-5. PMID: 23054468.
- Stevens SM, et al.; Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. *J Thromb Thrombolysis.* 2016 Jan;41(1):154-64. doi: 10.1007/s11239-015-1316-1. PMID: 26780744; PMCID: PMC4715840.

Clinical Evidence Levels

● Strong

- Includes gene-drug pairs approved by the Coriell Institute for Medical Research Pharmacogenomics Advisory Group.
- Includes gene-drug pairs supported by multiple studies documenting consistent effects of specific genetic variant(s) on clinical outcomes.
- Includes gene-drug pairs approved by the Dutch Pharmacogenetics Working Group (DPWG) and/or guidelines published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC).

● Moderate

- Includes gene-drug pairs supported by pharmacokinetic, pharmacodynamic, or molecular/cellular functional studies showing consistent effects of genetic variant(s).
- Includes Drug product information (e.g. This interpretation is based on guidance available in the FDA (Food and Drug Administration) drug label for ABILIFY® (10/2013).
- Includes gene-drug pairs for which potential clinical outcomes are inferred from similar gene-drug interactions approved by the Dutch Pharmacogenetics Working Group (DPWG), and/or guidelines published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC), and/or pharmacogenomic reports and submission from the Coriell Institute for Medical Research.

○ Emerging

- Includes gene-drug pairs supported by published studies of the drug, related drug, or a probing compound of interest involving limited data and/or inconsistent findings.

Disclaimer: These tests were developed and characterized by Intermountain Precision Genomics. The tests in Intermountain Precision Genomics's pharmacogenetics panel have not been approved by the Food and Drug Administration. The FDA has determined that such approval is not necessary, provided that the laboratory both (1) maintains its good standing as a clinical testing laboratory with all mandatory accrediting bodies, and (2) continually demonstrates that its testing protocols and procedures achieve a high degree of analytical accuracy. Reads are aligned to human genome reference sequence (GrCh37) using the Kailos Blue pipeline v5.4.7. While this test is able to detect deletions and duplications of the CYP2D6 gene, the assay has not been validated to specify the exact number of copies that may occur as a result of a duplication event in this gene. Results indicating that a duplication of CYP2D6 was detected should be interpreted with the understanding that more than three copies of the gene cannot be excluded and therefore close monitoring of patient medication response is recommended.

Limitation: This test will not detect all the known alleles that result in altered or inactive tested genes. This test does not account for all individual variations in the individual tested. Absence

RS-21-0000052A - XYTEST, Name - Reported Aug 17, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history and current treatment regimen. Portions © 2014-2021 Coriell Life Sciences, Inc.

Powered by:
CORIELL
LIFE SCIENCES

of a detectable gene mutation does not rule out the possibility that a patient has different phenotypes due to the presence of an undetected polymorphism or due to other factors such as drug-drug interactions, comorbidities and lifestyle habits.

Methodology: Illumina MiSeq System sequencing.

Laboratory Certification: CLIA # 46D2094383

Laboratory Director: Jeremy Wallentine

Genetic Summary

Gene	Result	Activity †
ABCG2	G G	Normal function
ADRA2A(C-1291G)	C C	Multiple statuses; see per-drug detail
COMT(Val158Met)	G A	Decreased function
CYP1A2	*1A *1L	Unknown Metabolizer
CYP2C19	*2 *2	Poor metabolizer
CYP2C9	*1 *1	Normal metabolizer
CYP2D6	*1A *2B or *34 *39; or *1A *2A	Normal metabolizer
CYP3A4	*1 *1A; or *1A *1A; or *1 *1	Normal metabolizer
CYP3A5	*3A *3A	Poor metabolizer
DPYD	*1 *5	Normal function
Factor V Leiden	Normal	See Thrombosis Profile
G6PD	B (WT) B (WT)	Normal function
GRIK4	T C	Uncertain function
HTR2A	A G	Uncertain function
MTHFR	GG GG	Decreased function
MTHFR (A1298C)	Variant	See Thrombosis Profile
MTHFR (C677T)	Normal	See Thrombosis Profile
OPRM1(A118G)	A A	Normal function
Prothrombin (F2)	Normal	See Thrombosis Profile
SLCO1B1	*1 *1	Normal liver uptake activity
TPMT	*1 *1	Normal metabolizer
VKORC1	*1 *1	Low sensitivity to warfarin